Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 3
2005 6
2006 8
2007 9
2008 7
2009 9
2010 14
2011 16
2012 7
2013 17
2014 10
2015 9
2016 10
2017 8
2018 17
2019 25
2020 29
2021 37
2022 38
2023 31
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

299 results

Results by year

Filters applied: . Clear all
Page 1
Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells.
Rajasekaran N, Wang X, Ravindranathan S, Chin DJ, Tseng SY, Klakamp SL, Widmann K, Kapoor VN, Vexler V, Keegan P, Yao S, LaVallee T, Khare SD. Rajasekaran N, et al. Among authors: yao s. Cancer Immunol Immunother. 2024 Feb 24;73(3):60. doi: 10.1007/s00262-024-03635-3. Cancer Immunol Immunother. 2024. PMID: 38400933 Free PMC article.
Comparison of Clinical Characteristics, Therapy, and Short-Term Prognosis between Blunt and Penetrating Abdominal Trauma: A Multicentric Retrospective Cohort Study.
Liu Y, Gao Y, Chen Z, Cui J, Liang W, Wang Z, Sun L, Pang C, Lv Y, Liu G, Lu T, Zhang G, Dong X, Xu H, Yao S, Liang F, Liu G, Chen G, He J, Xu W, Wei B, Xi H, Chen L. Liu Y, et al. Among authors: yao s. Emerg Med Int. 2024 Feb 13;2024:5215977. doi: 10.1155/2024/5215977. eCollection 2024. Emerg Med Int. 2024. PMID: 38380077 Free PMC article.
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.
Lu S, Zhang W, Wu L, Wang W, Zhang P; Neotorch Investigators; Fang W, Xing W, Chen Q, Yang L, Mei J, Tan L, Sun X, Xu S, Hu X, Yu G, Yu D, Yang N, Chen Y, Shan J, Xing L, Tian H, Zhang X, Zhou M, Fang H, Wu G, Liu Y, Ye M, Cao L, Jiang J, Li X, Zhu L, Li D, Kang M, Zhong A, Chen K, Wu N, Sun Q, Ma H, Cai K, Wang C, Lin G, Zhu K, Zhang Y, Zhang X, Hu H, Zhang W, Chen J, Yang Z, Hang X, Hu J, Huang Y, Zhang Z, Zhang L, Zhang L, Liu L, Lin D, Zhang J, Chen G, Li Y, Zhu L, Wang W, Yu W, Cao D, Keegan P, Yao S. Lu S, et al. Among authors: yao s. JAMA. 2024 Jan 16;331(3):201-211. doi: 10.1001/jama.2023.24735. JAMA. 2024. PMID: 38227033 Clinical Trial.
299 results